A Phase 3, open-label, rollover study to evaluate the safety and efficacy of long-term treatment with tezacaftor in combination with ivacaftor in subjects with cystic fibrosis aged 6 years and old-er, homozygous or heterozygous for the F508del-CFTR mutation (VX17-661-116)